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Abstract
Background: Androgen ablation is one of the viable therapeutic options for patients with primary hormone 
(androgen)-dependent prostate cancer. However, an antibiotic brefeldin A (BFA) has been shown to exhibit the growth 
inhibitory effect on human cancer cells. We thus investigated if BFA might inhibit proliferation of androgen-responsive 
prostate cancer LNCaP cells and also explored how it would be carried out, focusing on cell cycle and androgen 
receptor (AR).
Methods: Androgen-mediated cellular events in LNCaP cells were induced using 5α-dihydrotestosterone (DHT) as an 
androgenic mediator. Effects of BFA on non-DHT-stimulated or DHT-stimulated cell growth were assessed. Its growth 
inhibitory mechanism(s) was further explored; performing cell cycle analysis on a flow cytometer, assessing AR activity 
by AR binding assay, and analyzing AR protein expression using Western blot analysis.
Results: DHT (1 nM) was capable of stimulating LNCaP cell growth by ~40% greater than non-stimulated controls, 
whereas BFA (30 ng/ml) completely inhibited such DHT-stimulated proliferation. Cell cycle analysis showed that this 
BFA-induced growth inhibition was associated with a ~75% reduction in the cell number in the S phase and a 
concomitant increase in the G1 cell number, indicating a G1 cell cycle arrest. This was further confirmed by the 
modulations of specific cell cycle regulators (CDK2, CDK4, cyclin D1, and p21WAF1), revealed by Western blots. In 
addition, the growth inhibition induced by BFA was accompanied by a profound (~90%) loss in AR activity, which 
would be presumably attributed to the significantly reduced cellular AR protein level.
Conclusions: This study demonstrates that BFA has a potent growth inhibitory activity, capable of completely 
inhibiting DHT (androgen)-stimulated LNCaP proliferation. Such inhibitory action of BFA appears to target cell cycle 
and AR: BFA led to a G1 cell cycle arrest and the down-regulation of AR activity/expression, possibly accounting for its 
primary growth inhibitory mechanism. Thus, it is conceivable that BFA may provide a more effective therapeutic 
modality for patients with hormone-dependent prostate cancer.
Background
Although androgens are essential for the development and
growth of normal prostate, they are also responsible for the
development of benign prostatic hyperplasia and prostate
cancer [1]. Androgen ablation therapy is a viable treatment
modality for patients with primary hormone (androgen)-
dependent prostate cancer, lowering the serum androgen
level and blocking androgen receptor (AR)-mediated signal
transduction [2,3]. AR is a member of the steroid/nuclear
receptor super family [1,3] and its major biological role has
been well documented. Androgen binds to AR to form the
androgen-AR complex that is required for nuclear translo-
cation, followed by its binding to the androgen-responsive
element (ARE) for transcriptional activation of androgen-
responsive genes including prostate-specific antigen (PSA)
[4]. PSA is thus under the androgenic control and currently
the most commonly used biomarker for the diagnosis and
prognosis of prostate cancer, by measuring the level/
amount of serum PSA (secreted from prostate epithelial
cells) [5]. After all, AR is the primary factor transmitting an
androgenic signal to the nucleus for proliferation of prostate
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(cancer) cells as well as the regulation of androgen-medi-
ated cellular events.
Antiandrogens [2,6] such as cyproterone acetate, nilut-
amide, flutamide, bicalutamide etc. are then used to abolish
androgenic effects on prostate cancer cells, by competing
with androgen for AR binding to consequently slow down
or inhibit their growth. In addition, luteinizing hormone-
releasing hormone (LHRH) agonists (e.g., leuprolide, gos-
erelin, triptorelin etc.) [7] are also used to reduce availabil-
ity of circulating androgens to cancer cells by suppressing
testicular steroidogenesis (i.e. testosterone synthesis). In
some cases, the combinations of antiandrogens and LHRH
agonists are given to patients to improve treatment efficacy;
however, the overall efficacy of these trials has been shown
to be rather low with limited duration, resulting in an
almost inevitable cancer progression [3]. This led us to
assume that besides blocking the AR or manipulating the
androgen level, there must be a more effective modality for
managing hormone-dependent prostate cancer. We then
explored certain drugs/agents that directly and specifically
interfere with the androgen-mediated growth pathway in
prostate cancer.
Brefeldin A (BFA) [8], a fungal antibiotic, has been ini-
tially known to play a regulatory role in the intracellular
transport system [9-11]. It induces the reversible disassem-
bly of the Golgi complex, resulting in the interruption of
protein transport from the endoplasmic reticulum (ER) to
the Golgi [9,10]. BFA has been also shown to collapse the
Golgi complex into the ER, redistributing Golgi-associated
proteins/enzymes to the ER [11]. In addition, BFA has other
biological properties such as antitumor, antiviral, antifun-
gal, and antimitotic effects [10]. Particularly, BFA-induced
apoptosis and growth inhibition have been shown in several
human cancer cells, including leukemia, colon, prostate
(androgen-independent), and primary prostatic adenocarci-
noma cells [12-16]. Moreover, an in vitro screen of human
tumor cells conducted by the National Cancer Institute
(USA) also confirmed that BFA had a potent antiprolifera-
tive activity on several strains of prostate cancer cells [17].
Accordingly, we investigated the potential effect of BFA
on androgen-mediated prostate cancer cell growth, focusing
on the cell cycle [18] and AR regulation in androgen-
responsive prostate cancer LNCaP cells [19]. BFA was then
found to have a potent growth inhibitory activity, through a
blockage of the cell cycle progression and the down-regula-




The androgen-responsive human prostatic cancer LNCaP
cells were obtained from the American Type Culture Col-
lection (Rockville, MD) and grown in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS) and pen-
icillin/streptomycin (100 units/ml and 100 μg/ml). They
were maintained at 37°C in a humidified incubator in an
atmosphere of 95% air and 5% CO2. The medium was rou-
tinely changed every 3 days and cells were passaged or split
weekly with trypsinization. For experiments, androgen-
mediated cellular responses in LNCaP cells were studied
using the medium containing 5% charcoal-stripped fetal
bovine serum (CS-FBS) [20] in place of FBS, in which
endogenous steroids were removed to allow cells to primar-
ily respond to exogenously added androgens. Cells (2 × 105
cells/ml) were seeded in 6-well plates (2 ml/well) or T-75
flasks (10 ml/flask) and treated with brefeldin A (BFA)
(Epicentre Technologies, Madison, WI), DHT (5α-dihy-
drotestosterone) (NEN-DuPont, Boston, MA), or BFA/
DHT combination. As a stock BFA was prepared in etha-
nol, a vehicle culture was also set up by adding the same
amount of ethanol used in BFA to the cells. Cell numbers
were then determined at specified times by cell count using
the trypan blue exclusion method. All chemicals and
reagents used in this study have the great purity of at least
>95%.
Cell cycle analysis
Cell cycle phase distributions were determined on a FACS-
can flow cytometer (Becton-Dickinson) equipped with a
double discrimination module. Control or agents-treated
cells (~1 × 106 cells per condition) were harvested, washed
twice with phosphate-buffered saline (PBS), and resus-
pended in 500 μl of propidium iodide solution (20 μg/ml
propidium iodide, 0.2 mg/ml RNase, 0.2 mg/ml EDTA,
0.5% Nonidet P-40) for 1-h incubation at room temperature
in the dark. Following incubation, ~10,000 nuclei from
each sample were analyzed on a flow cytometer, and Cell-
Fit software was used to quantify cell cycle compartments
to estimate the % of cells distributed in the different cell
cycle phases.
Western blot analysis
The procedures essentially followed the protocol described
elsewhere [16]. Cell pellets from control or agents-treated
cells were resuspended in cell lysis buffer (10mM HEPES-
KOH, pH 7.5, 90mM KCl, 1.5mM Mg(OAc)2, 5% glycerol,
0.5% NP-40, 1mM DTT and 1mM PMSF). Cells lysates
were then prepared by freezing-thawing three times in liq-
uid nitrogen and their protein concentrations were deter-
mined using Coomassie protein assay reagent (Pierce,
Rockford, IL) on a spectrophotometer. An equal amount of
cell lysates (10 μg) was first subjected to 10% SDS-PAGE
(polyacrylamide gel electrophoresis), followed by protein
transfer to a nitrocellulose membrane with a semidry elec-
troblotter apparatus (MilliBlot, Millipore). After an over-
night blocking of membrane with 3% non-fat milk in TBST
(20mM Tris-HCl, pH 7.6, 137mM NaCl, 0.05% Tween-20),
the blot was incubated for 90 min with the primary antibod-Rajamahanty et al. Journal of Biomedical Science 2010, 17:5
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ies against CDK2, CDK4, cyclin D1, p21WAF1  (all pur-
chased from Santa Cruz Biotechnology, Santa Cruz, CA) or
AR (anti-AR from Affinity BioReagents, Golden, CO), fol-
lowed by a 30-min incubation with the appropriate second-
ary antibodies conjugated with peroxidase. After washing
the blot with PBS, specific immunoreactive proteins were
demonstrated by chemiluminescence, following the manu-
facturer's protocol (Kirkegaard and Perry Laboratories,
Gaithersburg, MD). The detected protein bands on the X-
ray film (autoradiogram) were then quantified using scan
densitometry (Silk Scientific, Oregon, UT).
Androgen receptor (AR) binding assay
The protocol was adopted from the method of Turcotte et
al. [21] with minor modifications. Radioactive methyl-
trienolone or R1881, the synthetic analog of DHT, was used
as a ligand for AR. After LNCaP cells were cultured with
BFA (30 ng/ml) for indicated times, they were washed with
a plain medium and incubated with 10 nM [3H]-R1881 (87
Ci/mmol, NEN-DuPont) for 2 h at 37°C in the presence or
absence of 100-fold excess of unlabeled DHT. Following
incubation, cells were washed extensively with PBS to
remove unbound radioactive ligand and then solubilized in
0.3N NaOH-ethanol (4:1; v/v) for 5 min. Those solubilized
cells were transferred to the scintillation vials for measuring
the radioactivity incorporated into AR (i.e. a ligand-AR
binding) using a scintillation counter. Specific AR-binding
was then normalized by subtracting non-specific binding
(background) and expressed by cpm/106 cells.
Tandem PSA assay
Cell lysates were prepared from control and BFA-treated
cells by freezing-thawing in liquid nitrogen as described
earlier. Either 100 μl aliquots of spent media or 10 μg of
cell lysates were used for Tandem-E PSA assay (Hybritech,
San Diego, CA). The quantitative measurement of PSA was
performed by following the manufacturer's assay proce-
dures.
Statistical analysis
All data were presented as mean ± SD (standard deviation)
and statistical differences between the groups were assessed
with the unpaired Student's t test. A value of p < 0.05 was
considered significant.
Results
Effect of BFA on cell growth
LNCaP cells were first cultured with the varying concentra-
tions (0-50 ng/ml) of BFA for 72 h, and their effects on cell
growth were assessed by cell count. Cell growth was signif-
icantly inhibited by BFA in a dose-dependent manner,
resulting in a 45, 78, and 95% growth reduction with 20, 30,
and 50 ng/ml of BFA, respectively (Fig. 1A). The moder-
ately effective BFA concentration of 30 ng/ml, which
appeared to be adequate for our purpose, was then used in
the rest of the studies. The cell viability test also indicated
that the growth inhibition induced by BFA (30 ng/ml) was
unlikely due to cell death, confirming an ~80% cell viabil-
ity. Since LNCaP cell proliferation is known to be regulated
by androgens [19], the effect of BFA on such an androgen-
responsive cell growth was next examined by culturing the
cells with DHT (1 nM), BFA (30 ng/ml), or BFA/DHT
combination in CS-FBS medium [20] for 72 h. As
expected, DHT indeed led to a ~40% greater cell growth
(than controls) but this stimulated growth was completely
inhibited by BFA, as evidenced by a drastic growth reduc-
tion with the BFA/DHT combination (Fig. 1B). Thus, these
results suggest that BFA could be a potent growth inhibitor,
interfering with the DHT-mediated growth pathway in
LNCaP cells.
Effects of BFA on cell cycle
To explore the underlying mechanism of BFA-induced
growth suppression, cell cycle analysis was performed on
the cells that had been treated with DHT (1 nM), BFA (30
ng/ml), or BFA/DHT combination (in CS-FBS medium) for
Figure 1 Effects of BFA on LNCaP cell growth. (A) Dose-dependent 
effects of BFA on LNCaP cell growth were assessed: after cells were cul-
tured with 0-50 ng/ml of BFA for 72 h, those viable cell numbers were 
determined and expressed by the percent (%) relative to cell number 
in control (100%). (B) Effects of BFA on DHT-stimulated cell growth 
were examined: cells were grown with DHT (1 nM), BFA (30 ng/ml), or 
their combination for 72 h, and cell growth was assessed by the % of 
controls. All data are mean ± SD (standard deviation) from three sepa-
rate experiments (*p < 0.05 compared with controls).
A
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72 h. Compared with control cells, a >35% increase (p <
0.05) in the S phase cell number (while a ~13% decrease in
the G1 cell number) was observed in DHT-treated cells (Fig.
2A), consistent with the accelerated growth rate (Fig. 1B).
In contrast, (compared with controls) a ~75% decrease (p <
0.01) in the S phase cell number, concomitant with a ~20%
increase (p < 0.05) in the G1 cell number, was seen with
sole BFA as well as BFA/DHT treatments (Fig. 2A), result-
ing in a significant growth reduction (Fig. 1B). These
results thus suggest that BFA appears to cause a blockage of
cells entering from the G1 to the S phase, i.e. a G1 cell cycle
arrest, ultimately leading to the growth cessation.
For confirmation, the effects of BFA were also examined
on the specific cell cycle regulators for the G1-S phase tran-
sition [18], including CDK2, CDK4, cyclin D1, and
p21WAF1. Cells treated with or without BFA (30 ng/ml) for
72 h were subjected to Western blot analysis, followed by
densitometric quantification. The expressions of CDK2,
CDK4, and cyclin D1 were significantly (>60%) reduced or
down-regulated (compared with controls), while p21WAF1
expression was up-regulated in BFA-treated cells (Fig. 2B).
This further supports the notion that BFA-induced growth
inhibition is associated with a G1 cell cycle arrest.
Effects of BFA on androgen receptor (AR) activity and 
expression
Since AR is a major factor playing an essential role in the
androgen-dependent prostate cancer growth [1], we then
examined the effects of BFA on (biological) activity and
expression of AR. First, AR activity was assessed by AR
binding assay, measuring the binding potential of AR to
DHT, in the cells treated with BFA (30 ng/ml) for 24, 48,
and 72 h. Such studies showed that AR binding activity was
significantly (~60%) decreased by 24-h BFA treatment and
further diminished by ~90% after 72 h (Fig. 3), indicating a
time-dependent, progressive loss in AR activity by BFA.
To better understand such a profound reduction in AR
activity, the cellular status (expression) of AR protein fol-
lowing DHT, BFA, or BFA/DHT treatments (in CS-FBS
medium) for 72 h was analyzed using Western blots.
Although AR expressions in both control and DHT-treated
cells were similarly high and apparent, BFA remarkably
down-regulated its expression by > 90% (Fig. 4A). This
study also revealed that DHT was unable to neutralize or
prevent BFA-induced AR diminution or BFA simply over-
came androgenic effect of DHT on AR integrity, resulting
Figure 2 Effects of BFA on cell cycle. (A) LNCaP cells were treated 
with DHT (1 nM), BFA (30 ng/ml), or BFA/DHT combination for 72 h and 
cell cycle analysis was performed as described in Methods. Cell cycle 
phase distributions or the number (%) of cells present at the G1, S, or 
G2/M phases in each experimental condition was determined and 
plotted. The data were mean ± SD from three separate experiments 
and subjected to statistical analysis; however, only those mean values 
(without SD) were used for plotting the graph for a clear illustration. (B) 
After cells were treated with or without BFA (30 ng/ml) for 72 h, the ex-
pressions of specific cell cycle regulators such as CDK2, CDK4, cyclin D1, 
and p21WAF1 were analyzed on Western blots and autoradiographs of 
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Figure 3 Effects of BFA on androgen receptor (AR) binding activ-
ity. Cells were cultured with BFA (30 ng/ml) for 24, 48, or 72 h, and AR 
binding assays were performed as described in Methods. Specific AR 
activity was calculated and expressed by cpm incorporated/106 cells. 
The data are mean ± SD from three independent experiments (*p < 
0.03 compared with controls at 0 h).Rajamahanty et al. Journal of Biomedical Science 2010, 17:5
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in only a marginal level of AR detected in BFA/DHT-
treated cells (Fig. 4A).
Moreover, a nearly complete disappearance or degrada-
tion of AR with BFA led us to assume that BFA might have
primarily targeted AR at the early time point. Such a possi-
bility was then tested by treating the cells with BFA (30 ng/
ml) for 6, 12, or 24 h, and AR expressions were analyzed on
Western blots and quantified with a scan densitometer. The
results showed that the AR level decreased to ~60% (p <
0.05) of the initial level after only 6-h BFA treatment and
steadily declined to 47% and 35% (p < 0.05) at 12 h and 24
h, respectively (Fig. 4B). Taken together, these studies dem-
onstrate that BFA is capable of progressively down-regulat-
ing AR expression, presumably accounting for a drastic
(~90%) loss in its binding (biological) activity at 72 h (Fig.
3).
Effect of BFA on androgen-regulated PSA secretion
As BFA appears to profoundly down-regulate AR expres-
sion, it was of interest to examine whether BFA might also
affect other androgen-mediated cellular events (via AR)
such as secretion of PSA, which is a useful biomarker for
prostate cancer and under the androgenic control [5].
LNCaP cells were cultured with BFA (30 ng/ml), DHT (1
nM), or BFA/DHT combination (in CS-FBS medium) for
72 h. Spent media were collected and assayed for the
amount of PSA secreted (to culture media) at the indicated
times. Time-dependent changes in secreted PSA are shown
in Fig. 5. Control cells secreted the measurable amount of
PSA although its levels seemed to gradually decline to 72 h.
However, BFA notably (p < 0.05 compared with controls)
inhibited PSA secretion throughout the experiments. In
contrast, DHT dramatically accelerated PSA secretion up to
a maximal 4.6-fold (p < 0.001 compared with controls) at
48 h and then its level considerably plunged by 72 h
(although it was yet significantly higher than controls).
However, this stimulatory effect of DHT (on PSA secre-
tion) was almost completely abolished by BFA, bringing its
PSA levels down to nearly the same as those in BFA alone.
Thus, these results illustrate that BFA is capable of inhibit-
ing PSA secretion, one of androgen-regulated cellular
events, presumably through abolishing DHT stimulatory
Figure 4 Effects of BFA on AR expression. (A) After cells were cul-
tured with BFA (30 ng/ml), DHT (1 nM), or BFA/DHT combination for 72 
h, cell lysates (10 μg) were prepared and analyzed for AR expression us-
ing Western blots and autoradiograph of those AR protein bands (110 
kDa) is shown. Beta (β)-actin is also shown as a protein loading control. 
(B) Following the exposure of cells to BFA (30 ng/ml) for 0, 6, 12, or 24 
h, the time-dependent reduction in AR expression was analyzed on 
Western blots. Intensities of AR expressions detected on autoradio-
graph were quantified using a scan densitometer and expressed by 
the arbitrary values (*p < 0.05) relative to controls (at 0 h) normalized to 
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Figure 5 Effect of BFA on PSA secretion regulated by DHT. Cells 
were cultured with BFA (30 ng/ml), DHT (1 nM), or BFA/DHT combina-
tion for 24, 48, and 72 h. Spent media were collected at each time point 
and assayed for secreted PSA. The amount of PSA secreted was ex-
pressed by ng/ml and all data are mean ± SD from three independent 
experiments (*p < 0.05; **p < 0.005 compared with controls).Rajamahanty et al. Journal of Biomedical Science 2010, 17:5
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action due to AR degradation (down-regulation of AR
expression) induced by BFA.
Discussion
In the present study, we examined the growth inhibitory
effect of BFA and also explored its inhibitory mechanism
on the androgen-responsive human prostate cancer LNCaP
cells in vitro. BFA demonstrated a potent growth inhibitory
activity on these cancer cells and completely suppressed
DHT-stimulated cell growth as well (Fig. 1B). This indi-
cates that BFA appears to interfere with the DHT-mediated
growth pathway in LNCaP cells. To have an insight into the
mode of BFA action against DHT, two parameters, namely
the cell cycle and the androgen receptor (AR), were sub-
jected to further investigations. Cell cycle analysis revealed
that BFA by itself caused a ~75% reduction in the S phase
cell number, indicating a typical G1 cell cycle arrest. Simi-
larly, BFA even blocked the DHT-stimulated G1-S phase
progression. This BFA-induced G1 arrest was further sup-
ported by the down-regulation of CDK2, CDK4, and cyclin
D1  while the up-regulation of p21WAF1, which were all
known to play the key roles in the G1-S phase transition
[18]. Thus, a cell cycle arrest in the G1 phase may at least in
part account for the BFA-induced growth inhibition in
LNCaP cells.
As AR is known to play a major role in the DHT-medi-
ated prostate cancer growth [3], possible effects of BFA
were examined on biological activity and cellular expres-
s i o n  o f  A R .  S u c h  s t u d i e s  s h o w e d  t h a t  A R  a c t i v i t y  a n d
expression were both extensively (>90%) reduced follow-
ing 72-h BFA treatment; particularly AR expression/protein
has declined to 60% in merely 6-h of BFA treatment (Fig.
4B). Moreover, DHT failed to reverse or prevent antagonis-
tic action of BFA on AR; in fact, BFA even severely dimin-
ished AR expression in DHT-stimulated cells to <10%
(compare DHT with BFA/DHT in Fig. 4A). Thus, regard-
less of the presence of DHT, BFA appears to abrogate the
cellular expression of AR. This BFA-mediated AR down-
regulation was also verified by the time-dependent reduc-
tion in AR expression (Fig. 4B). In conjunction with a cell
cycle arrest, these findings suggest that the BFA-induced
inhibition of DHT-stimulated LNCaP proliferation also
results from a loss of AR activity due to a diminution of AR
protein.
Although DHT, acting through the AR, is essential for the
growth of prostate cancer, the mechanism of androgen-
stimulated cell proliferation has not been fully defined. For
example, the signaling pathways responsible for the andro-
genic effects have been extensively studied [22], but the
actual roles of such androgen-regulated genes/proteins in
the mitogenic activity yet remain elusive. Meanwhile, the
importance of the cell cycle regulation has been reported in
the androgen-dependent proliferation of prostate cancer
cells [23-25]. Mitogenic signals of androgen were shown to
be mediated through multiple G1 regulatory elements/fac-
tors controlling the G1-S phase transition [23]. In fact, the
down-regulated expressions of cyclin D1, CDK2, and
CDK4 while the up-regulated p21WAF1 were associated with
a G1 growth arrest in LNCaP cells [24,25]. This finding was
also consistent with BFA-induced G1 cell cycle arrest in our
study (Fig. 2B). It is thus conceivable that a disruption of
androgen (via AR)-stimulated cell cycle progression by
BFA could be the vital mechanism of such a BFA-induced
growth inhibition.
In addition, the finding that BFA was capable of severely
down-regulating activity and expression of AR is rather sig-
nificant, and this may deserve further discussion to under-
stand and speculate exactly how BFA would carry it out to
fully block androgenic action. It is yet uncertain at present
whether the down-regulation of AR expression or AR deg-
radation may take place primarily at the transcriptional or
translational level. However, such BFA-induced AR degra-
dation might be likely due to the instability of newly syn-
thesized AR protein that failed to undergo the obligatory
post-translational modification. As AR is a phosphoprotein,
it needs to be post-translationally modified or phosphory-
lated in the Golgi complex to become matured and func-
tional [26]. It is yet possible that BFA could inhibit such
AR protein modification or maturation by blocking its
transport from the ER to the Golgi complex [8,9]. Due to
this BFA-interrupted AR phosphorylation, it is then plausi-
ble that unmodified AR protein would become rather unsta-
ble and susceptible to proteolysis, thereby being rapidly
degraded. This is one possible notion that may account for
how the AR protein level could be drastically reduced by
BFA, or rather, by BFA-activated protease. In fact, we have
been also exploring such protease(s) that would specifically
target AR protein. Although we have not yet completed the
study, the currently available data thus far indicate that
"proteasome" [27], a multicatalytic protease, appears to be
a primary candidate for targeting AR. We performed sev-
eral studies using the specific inhibitors for proteases and
proteasome to prevent BFA-induced AR degradation. We
then found that only the proteasome inhibitor, clasto-lacta-
cystin β-lactone (β-lac) [28], not other protease inhibitors,
was nearly completely capable of preventing AR degrada-
tion (data not shown). This finding suggests that BFA may
specifically activate proteasome targeting AR, supporting
the notion that AR degradation is primarily mediated
through BFA-activated proteasome. However, more studies
are required for further confirmation and also for defining
how BFA would actually activate proteasome.
Despite such compelling information, it cannot yet rule
out the possible effect of BFA on the transcriptional level of
AR (i.e. mRNA). In other words, if transcriptional activa-
tion of AR gene was somehow turned off by BFA, no ARRajamahanty et al. Journal of Biomedical Science 2010, 17:5
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mRNA would be transcribed, and no AR protein would be
subsequently translated. This is another possible notion that
the inhibition of AR transcription by BFA could lead to the
inhibition of AR de novo synthesis. Thus, the resulting
reduced level of AR protein is not due to AR degradation
mediated through proteasome as described above. As it is
critical to address the possible transcriptional regulation by
BFA, such study is currently underway in our laboratory.
In the meantime, our separate study of BFA effect on
PSA secretion (Fig. 5) may also provide useful information
on understanding the mechanism of BFA-blocked andro-
genic action. Such a study showed that DHT-stimulated
PSA secretion was completely inhibited/blocked by BFA,
possibly resulting from the preceding inhibition of AR tran-
scription. As PSA secretion follows its synthesis that is
directly under the androgenic (DHT) regulation via "AR",
the inhibition of PSA secretion indicates that no PSA gene
activation (required for PSA synthesis) would have been
followed because no AR transcription (required for AR
synthesis) had been carried out due to the inhibition of its
transcriptional activation by BFA. In other words, no AR
protein would be synthesized and available for activation of
PSA gene, resulting in no PSA synthesis and secretion. This
may then support the notion that the inhibition of DHT-
stimulated PSA secretion by BFA could mainly result from
the inhibition of AR transcription.
Taken all together, BFA-induced growth inhibition
appears to be primarily attributed to the greatly reduced AR
protein level, although whether "it" would result from AR
degradation  (through proteasome) or its transcriptional
inhibition remains uncertain at present. Further studies are
thus warranted and required.
Nevertheless, the fact remains the same that BFA has a
direct impact on AR, down-regulating its protein expres-
sion as well as its biological activity. This is indeed the pri-
mary mechanism, along with a cell cycle arrest, to induce
the growth inhibition by BFA in androgen-responsive pros-
tate cancer cells. In addition, previous studies also
described the BFA-induced growth inhibition in androgen-
independent prostate cancer cells [14,16] and primary cul-
tures of prostatic carcinomas [15]. Therefore, these findings
suggest that BFA may have the diverse growth inhibitory
effects on various types of prostate cancers as well as other
mammalian malignancies.
Conclusions
In summary, BFA has a potent growth inhibitory activity,
interfering with the androgen-mediated growth pathway in
LNCaP cells. Specifically, BFA appears to target cell cycle
and AR, inducing a G1 arrest and down-regulating AR
activity/expression, respectively. In particular, inactivation
of AR due to its degradation through BFA may primarily
account for the inhibition of androgen-stimulated LNCaP
cell growth. Thus, BFA could be considered a useful, effec-
tive adjuvant in ongoing androgen ablation therapy for hor-
mone-dependent prostate cancer. Further investigations are
warranted.
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